NEW DELHI – Glenmark Pharmaceuticals SA, a Swiss subsidiary of Mumbai, India-based Glenmark Pharmaceuticals Ltd., completed phase I trials in the Netherlands of BBR 830, a monoclonal antibody (MAb) that targets a class of activated immune cells that are involved in several autoimmune disorders.